Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recasimab for Lorlatinib-Induced Hypercholesterolemia
ChiCTR2600128150Phase 4Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of recasimab in hypercholesterolemia and combined dyslipidaemia, sponsored by Hunan Cancer Hospital. Primary endpoint: Percentage change in LDL-C from baseline at Week 16. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
recasimab
03
Conditions
hypercholesterolemiacombined dyslipidaemia
Beyond the preview
Go deeper on ChiCTR2600128150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128150.